相关实验视频
Updated: May 11, 2026
08:12
Intramyocardial Cell Delivery: Observations in Murine Hearts
Published on: January 24, 2014
13.5K
在心脏衰竭的老鼠中,对人类心脏周流体细胞进行心内注射改善了心脏功能
Yaping Xu1,2, Xiangli Zhang3, Zhikun Fu3
1Henan Key Laboratory of Cardiac Remodeling and Transplantation, Zhengzhou Seventh People's Hospital, Henan, People's Republic of China.
Stem cells and development
|August 19, 2024
概括
人类心周液衍生细胞 (hPFCs) 显示干细胞特性,并改善心力衰竭的老鼠的心脏功能. 在心脏周内给予hPFCs可减少纤维化和炎症,促进心脏的修复.
科学领域:
- 心血管生物学 心血管生物学
- 再生医学是一种再生医学.
- 干细胞疗法是一种干细胞疗法.
背景情况:
- 心力衰竭 (HF) 仍然是全球主要的死亡原因.
- doxorubicin (DOX) 是一种常见的化疗剂,可以诱导心脏毒性和高血压.
- 需要新的治疗策略来再生受损的心脏组织并改善心脏功能.
研究的目的:
- 研究人类心周液衍生细胞 (hPFCs) 的特征.
- 评估hPFCs在多克索鲁比诱导心力衰竭的小鼠模型中的治疗潜力.
- 评估心内hPFC给药对心脏功能,纤维化,炎症和血管生成的影响.
主要方法:
- 从心脏移植供体中分离出hPFC,并对干细胞标记物 (SCA-1,NANOG,CD90,CD105,CD73) 和分化潜力进行了表征.
- 在DOX诱导的HF大鼠中,HPFCs被输入心脏内.
- 评估了心脏功能,并在4周后进行了组织学,免疫组织化学和分子分析.
主要成果:
- hPFCs表现出干细胞特征和体外分化能力.
- 在DOX治疗的老鼠中,心内hPFC注射显著改善了心脏功能.
- hPFC治疗导致心脏纤维化减少,炎症性细胞因子 (IL-6,IL-10,TNF-α) 的水平降低,VEGFA表达增加.
- 植入的hPFCs在宿主心肌中表达了心脏标记物 (心脏热素T,连xin 43).
结论:
- hPFCs具有干细胞特性,并在心力衰竭的临床前模型中证明了治疗效果.
- 腹心内给予hPFCs通过减少纤维化和炎症,增强血管生成,促进心脏修复.
- 在心力衰竭中,hPFCs可能是再生疗法的有希望的细胞来源.
相关概念视频
01:17Pericarditis III: Medical Management
The primary objectives of managing pericarditis are to determine the underlying cause, provide effective therapy for treatment and symptom relief, and promptly detect signs and symptoms of cardiac tamponade. The following outlines the essential aspects of medical management for pericarditis:ObjectivesDetermine the Cause: Identifying the underlying cause of pericarditis is crucial for targeted treatment. Causes include viral infections, autoimmune diseases, post-cardiac injury syndrome, and...
01:25Pericarditis IV: Nursing Management
Pericarditis, an inflammation of the pericardium, necessitates diligent nursing management to ensure effective patient care and recovery. The initial step in managing pericarditis is a comprehensive patient medical assessment.The patient reports chest pain aggravated by breathing, coughing, and swallowing, which worsens when lying supine. The pain often improves when sitting up and leaning forward. Additional symptoms may include fever, malaise, and, in severe cases, signs of heart failure.
01:29Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
01:22Heart Failure VI: Adjunct Therapies
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
01:30Cardiomyopathy II: Dilated Cardiomyopathy
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...